Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Therapeutic Effects of Statins and Berberine on the Hyperlipemia

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2013 by Wenzhou Medical University
Sponsor:
Information provided by (Responsible Party):
JiFei Tang, Wenzhou Medical University
ClinicalTrials.gov Identifier:
NCT01697735
First received: September 28, 2012
Last updated: December 29, 2013
Last verified: December 2013

September 28, 2012
December 29, 2013
September 2012
June 2015   (final data collection date for primary outcome measure)
Change from baseline in combination statins with berberine on lipid level [ Time Frame: Measured at baseline, weeks 4 and 8 ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01697735 on ClinicalTrials.gov Archive Site
Adherence of statins and berberine treatment [ Time Frame: Measured at weeks 4 and 8 ] [ Designated as safety issue: No ]
Adherence of statins and berbeine treatment [ Time Frame: Measured at weeks 4 and 8 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
The Therapeutic Effects of Statins and Berberine on the Hyperlipemia
The Therapeutic Effects of Combination of Statins With Berberine on the Patients With Hyperlipemia:a Single-center, Open Clinical Trial

Statins are cholesterol-lowering medications that are often prescribed for patients with high cholesterol and who are at risk for cardiovascular disease (CVD). But there are many patients whose hyperlipemia are not well controlled. If investigators are simply doubling the statins, that only 6% of the benefit can be received. And it often has significant side effects in elder patients. Several studies have suggested that the use of berberine can effectively lower blood lipids. The chemical structure and mechanisms of drug is clearly, and the side effects are seldom, the price of berberine is very cheap. The purpose of this study is to observe the therapeutic effects of combination of statins and berberine on the patients with hyperlipemia whose level of the lipid are not well controlled when only using statins.

Patients at risk for cardiovascular disease (CVD) are often prescribed statins, which are medications that reduce the amount of cholesterol in the blood. By lowering cholesterol levels, these patients have a lower incidence of coronary artery disease, ischemic stroke, and peripheral arterial disease and so on. But there are many patients whose hyperlipemia are not well controlled.If investigators are simply doubling the statins, that only 6% of the benefit can be received.And it often bring significant side effects in elder patients. Several studies have suggested that the use of berberine can effectively lowering blood lipids.The chemical structure and mechanisms of drug is clearly, and the side effects are seldom, the price of berberine is very cheap. The purpose of this study is to observe the therapeutic effects of combination of statins and berberine on the patients with hyperlipemia whose level of the lipid are not well controlled when only using statins.

This study will enroll patients who currently take cholesterol-lowering medications,but the level of lipid is not controlled well. Patients will be assigned to receive 500mg of Berberine twice a day(meanwhile they are taking 20mg of Atorvastatin daily for 8 weeks or 10mg of Rosuvastatin daily for 8 weeks). Investigators will occur at baseline and Weeks 4 and 8. Blood will be collected for laboratory testing, and standardized psychological questionnaires will assess fatigue at baseline and weeks 4 and 8. Pill count will be used to assess adherence of Berberine and statins treatment at weeks 4 and 8. At weeks 4 and 8, medication side effects will be monitored and tests of alanine aminotransferase (ALT) and creatine phosphate kinase (CPK) will be performed. At weeks 4 and 8, medication efficacy will be assessed and test of low-density lipoprotein cholesterol (LDL-C) will be performed.

Interventional
Phase 4
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Dyslipidemias
  • Drug: Berberine;Atorvastatin or Rosuvastatin
    Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program,participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
    Other Names:
    • Berberine;
    • Liptor
    • Crestor
  • Drug: Atorvastatin or Rosuvastatin
    Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
    Other Names:
    • Liptor
    • Crestor
  • Experimental: Berberine;Atorvastatin or Rosuvastatin
    Follow the previous administration program,participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily; Besides taking statins, Participants will receive 500mg berberine twice a day for 8 weeks.
    Intervention: Drug: Berberine;Atorvastatin or Rosuvastatin
  • Active Comparator: Atorvastatin or Rosuvastatin
    Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
    Intervention: Drug: Atorvastatin or Rosuvastatin
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
June 2015
June 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Current use of lipid-lowering medications;
  2. Documented cardiovascular disease (CVD) by invasive or non-invasive testing (such as coronary angiography, nuclear imaging, stress echocardiography, carotid plaque on ultrasound), previous myocardial infarction (MI), acute coronary syndrome (ACS), coronary revascularization [percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG)] and other arterial revascularization procedures, ischaemic stroke, peripheral arterial disease(PAD);
  3. Patients with type 2 diabetes, patients with type 1 diabetes with target organ damage (such as microalbuminuria); Patients with moderate to severe chronic kidney disease [glomerular filtration rate (GFR) < 60 mL/min/1.73㎡];
  4. Markedly elevated single risk factors such as familial dyslipidaemias and severe hypertension;
  5. A calculated SCORE ≥1% for 10 year risk of fatal CVD

Exclusion Criteria:

  1. Cancer;
  2. HIV infected;
  3. Medical or psychiatric condition that prevents full study participation or follow-up (e.g., active psychosis);
  4. Active liver disease or unexplained persistent elevated transaminase levels;
  5. Major surgery or hospitalization in the 3 months prior to study entry;
  6. Current use of cyclosporin, erythromycin, clarithromycin, nefazodone, or any "azole" antifungals, including fluconazole, itraconazole, ketoconazole, mibefradil, or protease inhibitors;
  7. Female of childbearing potential;
  8. Severe gastrointestinal disease;
  9. With berberine using contraindications;
  10. Secondary hyperlipidemia
  11. Current participation in another clinical trial
Both
20 Years to 75 Years
No
China
 
NCT01697735
WZ medical college
No
JiFei Tang, Wenzhou Medical University
Wenzhou Medical University
Not Provided
Principal Investigator: Jifei Tang, MD Wenzhou Medical University
Wenzhou Medical University
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP